Lyka Labs Reports Q1 FY27 Financial Results; Consolidated Net Profit Surges 105.4% YoY

Pharmaceutical company Lyka Labs Limited has announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27), delivering strong top-line expansion driven by robust growth in export sales and domestic branded formulations.

Key Financial Highlights

Consolidated Net Total Income: Rose 26.95% year-on-year (YoY) to ₹4,272.79 lakhs in Q1 FY27, compared to ₹3,365.63 lakhs in Q1 FY26.

Standalone Net Total Income: Increased by 42.67% YoY to ₹4,272.79 lakhs.

Consolidated Net Profit: Surged by 105.44% YoY to ₹204.66 lakhs.

Standalone Net Profit: Advanced 159.04% YoY to ₹210.01 lakhs.

Export Revenue: Grew significantly by 68.03% YoY to reach ₹1,483.42 lakhs.

Domestic Revenue: Climbed 15.91% YoY to ₹2,652.11 lakhs.

Standalone Performance

For Q1 FY27, standalone revenue from operations reached ₹4,230.94 lakhs, marking a 45.01% YoY increase over ₹2,917.64 lakhs in Q1 FY26.

Standalone EBITDA stood at ₹501.12 lakhs, up 21.32% YoY from ₹413.06 lakhs in Q1 FY26. Standalone EBITDA margin stood at 11.84% in Q1 FY27 compared to 14.16% in Q1 FY26.

After accounting for other income of ₹41.85 lakhs, finance costs of ₹100.82 lakhs, and depreciation/amortization of ₹200.96 lakhs, standalone net profit after tax rose 70.75% YoY to ₹199.33 lakhs (compared to ₹116.74 lakhs in Q1 FY26).

Consolidated Performance

On a consolidated basis, revenue from operations for Q1 FY27 grew 28.11% YoY to ₹4,230.94 lakhs, compared to ₹3,302.54 lakhs in Q1 FY26.

Consolidated EBITDA rose 15.02% YoY to ₹496.57 lakhs (vs. ₹431.73 lakhs in Q1 FY26), with EBITDA margin coming in at 11.74% compared to 13.07% in Q1 FY26. Consolidated net profit after tax reached ₹194.80 lakhs, recording a 44.11% YoY increase over ₹135.17 lakhs in Q1 FY26.

Segmental Revenue Break-Up

1. Domestic Market (Total Sales: ₹2,652.11 Lakhs, +15.91% YoY)

Branded Formulation: ₹737.67 lakhs (+62.27% YoY vs. ₹454.58 lakhs in Q1 FY26)

Branded Veterinary: ₹587.35 lakhs (+97.83% YoY vs. ₹296.90 lakhs in Q1 FY26)

P2P: ₹1,327.09 lakhs (-13.64% YoY vs. ₹1,536.69 lakhs in Q1 FY26)

2. Export Market (Total Sales: ₹1,483.42 Lakhs, +68.03% YoY)

Branded Formulation: ₹1,483.42 lakhs (+68.03% YoY vs. ₹882.85 lakhs in Q1 FY26)

3. Other Income & Operating Revenue

Other Operating Income: ₹95.41 lakhs (-27.46% YoY vs. ₹131.52 lakhs in Q1 FY26)


Other Income: ₹41.85 lakhs (-33.67% YoY vs. ₹63.09 lakhs in Q1 FY26)

Shares of Lyka Labs Limited was last trading in BSE at Rs. 68.97 as compared to the previous close of Rs. 67.62. The total number of shares traded during the day was 2621 in over 16 trades.

The stock hit an intraday high of Rs. 68.97 and intraday low of 66.28. The net turnover during the day was Rs. 179243.00.

Source : Equity Bulls

Keywords

LykaLabs INE933A01014 Pharmaceuticals Q1FY27 Q1FY2027 ResultUpdate